Movement Disorders

Theresa Sevilis, DO, writes on picking a career path in medicine as a woman, and how deciding to jump ship from a traditional path was among the best decisions she's made.

The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]

For women, the decision to opt for an unconventional career path can be inspired by conflicting responsibilities and balancing life with work. But, as Sana Syed, MD, MPH, explains, following your passion is still an achievable dream despite these challenges.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Expert clinicians offer their insight on conducting trials in pediatric migraine, the pipeline of Alzheimer therapies, disorders of consciousness and COVID-19, and more.

Here's what is coming soon to NeurologyLive®.

After discontinuing dosing in the phase 3 GENERATION HD1 study in 2021, Roche is designing a new phase 2 trial for tominersen, its investigational antisense oligomer for Huntington disease.

In addition to improving constipation in patients with Parkinson disease, ENT-01 also helped improve Mini-Mental State Examination scores, an exploratory measure of cognition.

Neurology News Network for the week ending January 29, 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 28, 2022.

At 10 minutes post dose, all 3 AZ-009 dose groups showed a clear reduction from baseline in mean MDS-UPDRS part III score that was greater than for placebo.

Approximately 300 patients across 30 clinical centers will be included in the 36-week study evaluating the efficacy and safety of sodium oligomannate (GV-971), a medication currently approved for Alzheimer disease in China.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending January 22, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

After a post hoc analysis revealed promising results in a subgroup of younger adults with less disease burden, Ionis has announced that Roche will develop a new phase 2 trial.

Yumanity Therapeutics announced the hold, which was in response to an investigational new drug application submitted to the FDA in December 2021.

Habits of moderate-to-vigorous exercise were preferentially associated with slower decline of postural and gait stability, and work-related activity levels were primarily associated with slower deterioration of processing speed.

Here's what is coming soon to NeurologyLive®.

The results, which included data from more than 7000 patients with ET and almost 500,000 individuals overall, may help identify new common genetic risk factors for ET.

Neurology News Network for the week ending January 15, 2022. [WATCH TIME: 4 minutes]

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 14, 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The results of a phase 4 study demonstrate the efficacy of APOKYN® (apomorphine hydrochloride injection) treatment.

Although both are dopamine reuptake inhibitors, those on MAO-B inhibitors demonstrated greater mean PDQ-39 mobility scores and EuroQol 5-dimension 3-level scores over a median of 4.5 years.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending January 8, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 7, 2022.

Patients treated with valbenazine demonstrated favorable outcomes on all secondary outcomes over placebo, as well showed no new safety signals.